New liposomal drug shows promise in early trial for Hard-to-Treat cancers

NCT ID NCT03207672

Ongoing Disease control Sponsor: Eisai Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Feb 25, 2026 · Last updated May 15, 2026 · Updated 6 times

Summary

This early-phase study tests a new liposomal formulation of the drug E7389 in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and evaluate side effects. The study includes patients with breast cancer, adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Eisai Trial Site 1

Chuo-ku, Tokyo, Japan
Eisai Trial Site 10

Hidaka, Saitama, Japan
Eisai Trial Site 11

Kyoto, Japan
Eisai Trial Site 12

Fukuoka, Japan
Eisai Trial Site 2

Osaka, Japan
Eisai Trial Site 3

Kashiwa, Chiba, Japan
Eisai Trial Site 4

Koto-ku, Tokyo, Japan
Eisai Trial Site 5

Sapporo, Hokkaido, Japan
Eisai Trial Site 6

Yokohama, Kanagawa, Japan
Eisai Trial Site 7

Shinjuku-ku, Tokyo, Japan
Eisai Trial Site 8

Nishinomiya, Hyōgo, Japan
Eisai Trial Site 9

Bunkyo-ku, Tokyo, Japan

Conditions

Explore the condition pages connected to this study.

SOLID TUMOR